172 related articles for article (PubMed ID: 23845468)
1. IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma.
Tang H; Wei Q; Ge J; Jian W; Liu J; Zhong L; Fu B; Zhao T
Hum Pathol; 2013 Oct; 44(10):2167-72. PubMed ID: 23845468
[TBL] [Abstract][Full Text] [Related]
2. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
[TBL] [Abstract][Full Text] [Related]
3. The complementary role of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in diagnosis of Hodgkin's lymphoma.
Masoud R; Ibrahiem A; Tantawy D; Eldosoky I
Ann Diagn Pathol; 2019 Oct; 42():64-68. PubMed ID: 31319330
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.
Carbone A; Gloghini A; Volpe R
Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287
[TBL] [Abstract][Full Text] [Related]
5. CD15, CD30, and PAX5 evaluation in Hodgkin's lymphoma on fine-needle aspiration cytology samples.
Cozzolino I; Vitagliano G; Caputo A; Montella M; Franco R; Ciancia G; Selleri C; Zeppa P
Diagn Cytopathol; 2020 Mar; 48(3):211-216. PubMed ID: 31825183
[TBL] [Abstract][Full Text] [Related]
6. CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL).
Ranuhardy D; Suzanna E; Sari RM; Hadisantoso DW; Andalucia R; Abdillah A
Acta Med Indones; 2018 Apr; 50(2):104-109. PubMed ID: 29950528
[TBL] [Abstract][Full Text] [Related]
7. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
8. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas.
Rodig SJ; Savage KJ; Nguyen V; Pinkus GS; Shipp MA; Aster JC; Kutok JL
Am J Surg Pathol; 2005 Feb; 29(2):196-203. PubMed ID: 15644776
[TBL] [Abstract][Full Text] [Related]
9. [Expression of fragile histidine triad (FHIT) protein and its significance in diagnosing classical Hodgkin lymphoma].
Zhao P; Lü YL; Zhong M; Chen LH; Pu XL
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):289-91. PubMed ID: 16777001
[TBL] [Abstract][Full Text] [Related]
10. The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma.
Kim LH; Eow GI; Peh SC; Poppema S
Pathology; 2003 Oct; 35(5):428-35. PubMed ID: 14555388
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous follicle center lymphoma with Hodgkin and Reed-Sternberg-like cells: a new histopathologic variant.
Dilly M; Ben-Rejeb H; Vergier B; Feldis M; Toty L; Nohra O; Beylot-Barry M; Gros A; Merlio JP; Parrens M
J Cutan Pathol; 2014 Oct; 41(10):797-801. PubMed ID: 25099172
[TBL] [Abstract][Full Text] [Related]
12. The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment.
Dumitru AV; Țăpoi DA; Halcu G; Munteanu O; Dumitrascu DI; Ceaușu MC; Gheorghișan-Gălățeanu AA
Cells; 2023 Jul; 12(13):. PubMed ID: 37443818
[TBL] [Abstract][Full Text] [Related]
13. Reed-Sternberg-Like Cells in Non-Hodgkin Lymphomas.
Gomez-Gelvez JC; Smith LB
Arch Pathol Lab Med; 2015 Oct; 139(10):1205-10. PubMed ID: 26414463
[TBL] [Abstract][Full Text] [Related]
14. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
15. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
16. [Study on the origin of H/RS cell and their biological behavior in Hodgkin lymphoma by using multiple mark techniques].
Wang JF; Xi YF; Wang LX; Yin WD; Zhang JW; Gong FC
Zhonghua Xue Ye Xue Za Zhi; 2004 Oct; 25(10):579-82. PubMed ID: 15634588
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis.
Slack GW; Ferry JA; Hasserjian RP; Sohani AR; Longtine JA; Harris NL; Zukerberg LR
Leuk Lymphoma; 2009 Jun; 50(6):937-43. PubMed ID: 19455461
[TBL] [Abstract][Full Text] [Related]
18. CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma.
Hartmann S; Goncharova O; Portyanko A; Sabattini E; Meinel J; Küppers R; Agostinelli C; Pileri SA; Hansmann ML
Mod Pathol; 2019 Jan; 32(1):37-47. PubMed ID: 30140037
[TBL] [Abstract][Full Text] [Related]
19. 3D connectomes of reactive and neoplastic CD30 positive lymphoid cells and surrounding cell types.
Lumer L; Wurzel P; Scharf S; Schäfer H; Ackermann J; Koch I; Hansmann ML
Acta Histochem; 2021 Jul; 123(5):151750. PubMed ID: 34233254
[TBL] [Abstract][Full Text] [Related]
20. An Epstein-Barr virus-positive classical Hodgkin lymphoma with exclusive sinusoidal growth pattern: An unusual morphologic variant.
Su P; Jug R; Liu X; Wang E
Pathol Res Pract; 2017 Jun; 213(6):710-712. PubMed ID: 28552534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
